Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Rating of “Moderate Buy” from Analysts

by · The Markets Daily

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $51.8571.

A number of equities analysts have recently weighed in on JBIO shares. BTIG Research upped their price target on shares of Jade Biosciences from $39.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Guggenheim reiterated a “buy” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Tuesday, June 2nd. UBS Group began coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a “buy” rating and a $45.00 target price on the stock. Wedbush restated an “outperform” rating and set a $47.00 target price on shares of Jade Biosciences in a research report on Monday. Finally, Wall Street Zen cut shares of Jade Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

Check Out Our Latest Stock Analysis on Jade Biosciences

Jade Biosciences Price Performance

Shares of NASDAQ JBIO opened at $21.73 on Thursday. The stock has a fifty day moving average price of $19.75 and a 200 day moving average price of $18.57. Jade Biosciences has a 1-year low of $6.67 and a 1-year high of $28.00. The company has a market cap of $1.07 billion, a PE ratio of -10.76 and a beta of 1.49.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Analysts anticipate that Jade Biosciences will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jade Biosciences

A number of large investors have recently added to or reduced their stakes in JBIO. Legal & General Group Plc purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $29,000. Russell Investments Group Ltd. purchased a new position in Jade Biosciences during the second quarter worth $31,000. BNP Paribas Financial Markets purchased a new position in Jade Biosciences during the second quarter worth $32,000. California State Teachers Retirement System raised its holdings in shares of Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after acquiring an additional 819 shares during the last quarter. Finally, Group One Trading LLC raised its holdings in shares of Jade Biosciences by 122.9% in the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock worth $65,000 after acquiring an additional 22,527 shares during the last quarter.

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

Further Reading